个性化文献订阅>文章检索

文章名     作者     期刊名     摘要     卷     期         如果没有找到您所需要的文献，请点击 ——此处申请     共9条记录   Olaparib. PARP-1 and PARP-2 inhibitor, Oncolytic. [作者：Vasiliou, S; Castaner, R; Bolos, J,期刊：Drugs of the Future, 页码：101-105 , 文章类型： Article，,卷期：2009年34-2] Olaparib is a potent inhibitor of poly [ADP-ribose] polymerases PARP-1 and PARP-2 that is currently undergoing clinical development for the treatment of BRCA1/2-defective breast, ovarian, pancreatic and colorectal tumors... Saracatinib. Dual Src/ABL kinase inhibitor, Oncolytic. [作者：Dulsat, C; Mealy, N; Castaner, R,期刊：Drugs of the Future, 页码：106-114 , 文章类型： Article，,卷期：2009年34-2] Tumor development is usually triggered by abnormalities in complex signaling pathways involved in normal cell growth, activity and function. Src kinase has been identified as a critical signaling pathway involved in tumo... Tosedostat. Aminopeptidase inhibitor, Oncolytic. [作者：Owen, RT; Castaner, R; Bolos, J,期刊：Drugs of the Future, 页码：115-118 , 文章类型： Article，,卷期：2009年34-2] Tosedostat (CHR-2797) is on orally active aminopeptidase inhibitor that is converted in vivo to a pharmacologically active metabolite, CHR-79888, and exerts on antiproliferative effect against a wide range of leukemic an... Darinaparsin. Organic arsenical, Apoptosis inducer, Oncolytic. [作者：Campas, C; Castaner, R,期刊：Drugs of the Future, 页码：97-100 , 文章类型： Article，,卷期：2009年34-2] Darinaparsin is a novel organic arsenic molecule synthesized by conjugating dimethylarsenic to glutathione. Its mechanism of action involves targeted disruption of mitochondrial function, modified signal transduction and... NEW APPROACHES TO OVERCOMING BACTERIAL RESISTANCE [作者：Fukuda, Y,期刊：Drugs of the Future, 页码：127-136 , 文章类型： Review，,卷期：2009年34-2] The worldwide spread of drug-resistant bacteria is now a critical problem in global healthcare. Hence, the continuous development of effective antibacterial drugs for the treatment of severe infections caused by drug-res... THE SIGMA-1 (sigma(1)) RECEPTOR AND ITS ROLE IN THE TREATMENT OF MOOD DISORDERS [作者：Hayashi, T; Stahl, SM,期刊：Drugs of the Future, 页码：137-146 , 文章类型： Review，,卷期：2009年34-2] Sigma (sigma) receptors have long been implicated in a variety of neuronal and brain functions, although their precise biochemical and physiological role, and potential involvement in neurological and psychiatric disorde... GHRELIN RECEPTOR AGONISTS FOR THE TREATMENT OF GASTRIC EMPTYING DISORDERS [作者：Meerveld, BGV; Venkova, K,期刊：Drugs of the Future, 页码：119-125 , 文章类型： Review，,卷期：2009年34-2] Delayed gastric emptying, also known as gastroparesis or gastric stasis, is a common complication of a variety of gastrointestinal (GI) and systemic diseases. The strategies used to alleviate symptoms of gastroparesis in... GAUCHER'S DISEASE [作者：Dulsat, C; Mealy, N,期刊：Drugs of the Future, 页码：147-149 , 文章类型： Article，,卷期：2009年34-2] Approved treatments for the lysosomal storage syndrome Gaucher's disease include enzyme replacement therapy (imiglucerase, Cerezyme (R); Genzyme Therapeutics) and substrate inhibition therapy (miglustat, Zavesca (R); Act... THERAPEUTIC TARGETS FOR BIPOLAR DISORDER [作者：Sorbera, LA; Dulsat, C; Rosa, E,期刊：Drugs of the Future, 页码：151-158 , 文章类型： Article，,卷期：2009年34-2] Bipolar disorder is a psychiatric illness characterized by aromatic mood swings in which on individual experiences periods of highs (euphoria) and lows (sadness), referred to as episodes of mania and depression, respecti...